USANA Health Sciences (USNA) 10-Q 6 Aug 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 29, 2024	Aug. 02, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 29, 2024
Document Transition Report	false
Entity File Number	001-35024
Entity Registrant Name	USANA HEALTH SCIENCES, INC.
Entity Incorporation, State or Country Code	UT
Entity Tax Identification Number	87-0500306
Entity Address, Address Line One	3838 West Parkway Blvd.
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84120
City Area Code	801
Local Phone Number	954-7100
Title of 12(b) Security	Common Stock
Trading Symbol	USNA
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,052,276
Entity Central Index Key	0000896264
Current Fiscal Year End Date	--12-28
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Current assets
Cash and cash equivalents	$ 332,423	$ 330,420
Inventories	61,832	61,454
Prepaid expenses and other current assets	24,826	25,872
Total current assets	419,081	417,746
Property and equipment, net	97,686	99,814
Goodwill	16,837	17,102
Intangible assets, net	28,637	29,919
Deferred tax assets	18,190	13,284
Other assets	50,988	54,892
Assets, total	631,419	632,757
Current liabilities
Accounts payable	6,648	10,070
Line of credit - short term	0	786
Other current liabilities	97,248	107,989
Total current liabilities	103,896	118,845
Deferred tax liabilities	4,653	4,552
Other long-term liabilities	10,662	12,158
Stockholders' equity
Common stock, $0.001 par value; Authorized -- 50,000 shares, issued and outstanding 19,051 as of June 29, 2024 and 19,130 as of December 30, 2023	19	19
Additional paid-in capital	68,814	65,661
Retained earnings	463,883	445,217
Accumulated other comprehensive income (loss)	(20,508)	(13,695)
Total stockholders' equity	512,208	497,202
Liabilities and equity, total	$ 631,419	$ 632,757

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands	Jun. 29, 2024	Dec. 30, 2023
Statement of Financial Position [Abstract]
Common stock, par or stated value per share (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, shares, issued (in shares)	19,051	19,130
Common stock, shares, outstanding (in shares)	19,051	19,130

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Income Statement [Abstract]
Net sales	$ 212,869	$ 238,202	$ 440,669	$ 486,562
Cost of sales	40,333	43,326	83,402	91,845
Gross profit	172,536	194,876	357,267	394,717
Operating expenses:
Associate incentives	90,371	102,380	186,129	208,450
Selling, general and administrative	64,325	68,096	128,625	135,022
Total operating expenses	154,696	170,476	314,754	343,472
Earnings from operations	17,840	24,400	42,513	51,245
Other income (expense):
Interest income	2,763	2,224	5,439	3,999
Interest expense	(51)	(43)	(103)	(74)
Other, net	(349)	229	(535)	141
Other income (expense), net	2,363	2,410	4,801	4,066
Earnings before income taxes	20,203	26,810	47,314	55,311
Income taxes	9,771	9,518	20,345	19,636
Net earnings	$ 10,432	$ 17,292	$ 26,969	$ 35,675
Earnings per common share
Basic (in dollars per share)	$ 0.55	$ 0.89	$ 1.41	$ 1.85
Diluted (in dollars per share)	$ 0.54	$ 0.89	$ 1.40	$ 1.84
Weighted average common shares outstanding
Basic (in shares)	19,073	19,321	19,123	19,302
Diluted (in shares)	19,159	19,427	19,230	19,377
Comprehensive income:
Net earnings	$ 10,432	$ 17,292	$ 26,969	$ 35,675
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(1,846)	(7,957)	(6,948)	(6,303)
Tax benefit (expense) related to foreign currency translation adjustment	(69)	516	135	614
Other comprehensive income (loss), net of tax	(1,915)	(7,441)	(6,813)	(5,689)
Comprehensive income	$ 8,517	$ 9,851	$ 20,156	$ 29,986

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2022		19,206,000
Beginning balance at Dec. 31, 2022	$ 434,472	$ 19	$ 55,604	$ 391,636	$ (12,787)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	35,675			35,675
Other comprehensive income (loss), net of tax	(5,689)				(5,689)
Equity-based compensation expense	$ 7,282		7,282
Common stock repurchased and retired (in shares)	0
Common stock issued under equity award plans (in shares)		92,000
Common stock issued under equity award plans	$ 0
Tax withholding for net-share settled equity awards	(2,916)		(2,916)
Ending balance (in shares) at Jul. 01, 2023		19,298,000
Ending balance at Jul. 01, 2023	468,824	$ 19	59,970	427,311	(18,476)
Beginning balance (in shares) at Apr. 01, 2023		19,294,000
Beginning balance at Apr. 01, 2023	455,354	$ 19	56,351	410,019	(11,035)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	17,292			17,292
Other comprehensive income (loss), net of tax	(7,441)				(7,441)
Equity-based compensation expense	3,674		3,674
Common stock issued under equity award plans (in shares)		4,000
Common stock issued under equity award plans	0
Tax withholding for net-share settled equity awards	(55)		(55)
Ending balance (in shares) at Jul. 01, 2023		19,298,000
Ending balance at Jul. 01, 2023	$ 468,824	$ 19	59,970	427,311	(18,476)
Beginning balance (in shares) at Dec. 30, 2023	19,130,000	19,130,000
Beginning balance at Dec. 30, 2023	$ 497,202	$ 19	65,661	445,217	(13,695)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	26,969			26,969
Other comprehensive income (loss), net of tax	(6,813)				(6,813)
Equity-based compensation expense	$ 7,403		7,403
Common stock repurchased and retired (in shares)	(194,000)	(194,000)
Common stock repurchased and retired	$ (9,483)		(1,180)	(8,303)
Common stock issued under equity award plans (in shares)		115,000
Common stock issued under equity award plans	0
Tax withholding for net-share settled equity awards	$ (3,070)		(3,070)
Ending balance (in shares) at Jun. 29, 2024	19,051,000	19,051,000
Ending balance at Jun. 29, 2024	$ 512,208	$ 19	68,814	463,883	(20,508)
Beginning balance (in shares) at Mar. 30, 2024		19,047,000
Beginning balance at Mar. 30, 2024	499,988	$ 19	65,111	453,451	(18,593)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	10,432			10,432
Other comprehensive income (loss), net of tax	(1,915)				(1,915)
Equity-based compensation expense	3,734		3,734
Common stock issued under equity award plans (in shares)		4,000
Common stock issued under equity award plans	0
Tax withholding for net-share settled equity awards	$ (31)		(31)
Ending balance (in shares) at Jun. 29, 2024	19,051,000	19,051,000
Ending balance at Jun. 29, 2024	$ 512,208	$ 19	$ 68,814	$ 463,883	$ (20,508)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
Cash flows from operating activities
Net earnings	$ 26,969	$ 35,675
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities
Depreciation and amortization	6,971	6,519
Right-of-use asset amortization	3,815	3,846
(Gain) loss on sale of property and equipment	17	(12)
Equity-based compensation expense	7,403	7,282
Deferred income taxes	(4,918)	(5,026)
Inventory write-down	1,512	2,684
Changes in operating assets and liabilities:
Inventories	(4,486)	(550)
Prepaid expenses and other assets	225	1,986
Accounts payable	(3,310)	(1,171)
Other liabilities	(8,525)	(28,849)
Net cash provided by (used in) operating activities	25,673	22,384
Cash flows from investing activities
Proceeds from the settlement of net investment hedges	1,125	3,775
Payments for net investment hedge	(870)	(1,271)
Proceeds from sale of property and equipment	3	13
Purchases of property and equipment	(5,872)	(5,716)
Net cash provided by (used in) investing activities	(5,614)	(3,199)
Cash flows from financing activities
Repurchase of common stock	(9,444)	0
Borrowings on line of credit	691	750
Payments on line of credit	(1,476)	(750)
Payments related to tax withholding for net-share settled equity awards	(3,070)	(2,916)
Payments for contingent consideration	0	(338)
Net cash provided by (used in) financing activities	(13,299)	(3,254)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(4,831)	(4,310)
Net increase (decrease) in cash, cash equivalents, and restricted cash	1,929	11,621
Cash, cash equivalents, and restricted cash at beginning of period	333,246	291,320
Cash, cash equivalents, and restricted cash at end of period	335,175	302,941
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents	332,423	300,183
Restricted cash included in other assets	2,752	2,758
Total cash, cash equivalents, and restricted cash	335,175	302,941
Cash paid during the period for:
Interest	72	3
Income taxes	26,572	28,817
Cash received during the period for:
Income tax refund	5	680
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease obligations	613	4,688
Accrued purchases of property and equipment	57	132
Accrued excise tax for repurchase of common stock	$ 39	$ 0

Organization, Consolidation, an

Organization, Consolidation, and Basis of Presentation	6 Months Ended
	Jun. 29, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation, and Basis of Presentation	ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION USANA Health Sciences, Inc. is a global direct-selling, personal health and wellness company that develops and manufactures high quality, science-based nutritional and personal care products. The Condensed Consolidated Financial Statements (the “Financial Statements”) include the accounts and operations of the Company, which are grouped and presented in two geographic regions: (1) Asia Pacific, and (2) Americas and Europe. Asia Pacific is further divided into three sub-regions: (i) Greater China, (ii) Southeast Asia Pacific, and (iii) North Asia. The countries included in these regions and sub-regions are described below: (1) Asia Pacific - (i) Greater China – Hong Kong, Taiwan, and China. The Company’s business in China is conducted by BabyCare Holdings, Ltd., the Company’s wholly-owned subsidiary. (ii) Southeast Asia Pacific – Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, Indonesia and India (1) . (iii) North Asia – Japan and South Korea. (2) Americas and Europe – United States, Canada, Mexico, Colombia, and Europe (the United Kingdom, France, Germany, Spain, Italy, Romania, Belgium, and the Netherlands). (1) We commenced operations in this market near the end of the fourth quarter of 2023. The condensed consolidated balance sheet as of December 30, 2023, derived from audited consolidated financial statements, and the unaudited interim condensed consolidated financial information of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X promulgated by the SEC. Accordingly, certain information and disclosures that are normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. In the opinion of the Company’s management, the accompanying interim condensed consolidated financial information contains all adjustments, consisting only of normal recurring adjustments that are necessary to state fairly the Company’s financial position as of June 29, 2024, and results of operations and cash flows for the three and six months ended June 29, 2024 and July 1, 2023. The interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto that are included in the Company’s Annual Report on Form 10-K for the year ended December 30, 2023. The results of operations for the three and six months ended June 29, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending December 28, 2024. Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications relate to the disaggregation of inventory write-downs from changes in inventories within operating activities of the condensed consolidated statements of cash flows. NOTE A – ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION - CONTINUED Recent Accounting Pronouncements Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The standard is intended to provide financial statement users with more disaggregated expense information about a public entity’s reportable segments. ASU 2023-07 requires incremental disclosures related to a public entity’s reportable segments including allowing the disclosure of multiple measures of segment profit or loss, requiring the disclosure of significant segment expenses, and requiring the qualitative disclosure of other segment items. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, and should be adopted retrospectively unless impracticable. Early adoption is permitted. The Company is currently evaluating the impact adoption of the standard will have on its consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The standard is intended to benefit investors by providing more detailed income tax disclosures. ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact adoption of the standard will have on its consolidated financial statements. No other recent accounting pronouncements had, or are expected to have, a material impact on the Company's condensed consolidated financial statements.

Fair Value Measures

Fair Value Measures	6 Months Ended
	Jun. 29, 2024
Fair Value Disclosures [Abstract]
Fair Value Measures	FAIR VALUE MEASURES The Company measures, at fair value, certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are: • Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date. • Level 2 inputs are from other than quoted market prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. • Level 3 inputs are unobservable and are used to measure fair value in situations where there is little, if any, market activity for the asset or liability at the measurement date. NOTE B – FAIR VALUE MEASURES - CONTINUED As of June 29, 2024, and December 30, 2023, the following financial assets and liabilities were measured at fair value on a recurring basis using the type of inputs shown: June 29, Fair Value Measurements Using Inputs Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 262,235 $ 262,235 $ — $ — Foreign currency contracts included in other current liabilities (103) — (103) — Deferred compensation liabilities included in other long-term liabilities (4,075) — (4,075) — December 30, Fair Value Measurements Using Inputs Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 258,319 $ 258,319 $ — $ — Foreign currency contracts included in other current liabilities (62) — (62) — Deferred compensation liabilities included in other long-term liabilities (3,137) — (3,137) — There were no transfers of financial assets or liabilities between levels of the fair value hierarchy for the periods indicated. The majority of the Company’s non-financial assets, which include long-lived assets, are not required to be carried at fair value on a recurring basis. However, if an impairment charge is required, a non-financial asset would be written down to fair value. As of June 29, 2024 and December 30, 2023, none of the Company's non-financial assets were measured at fair value. As of June 29, 2024 and December 30, 2023, the Company’s financial instruments include cash equivalents and restricted cash. The recorded values of cash equivalents and restricted cash approximate their fair values, based on their short-term nature.

Inventories

Inventories	6 Months Ended
	Jun. 29, 2024
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Inventories consist of the following: June 29, December 30, Raw materials $ 21,901 $ 19,848 Work in progress 4,306 4,707 Finished goods 35,625 36,899 Inventories $ 61,832 $ 61,454 Noncurrent inventories $ 3,075 $ 3,128 As of June 29, 2024, noncurrent inventories consisted of $1,883 of raw materials and $1,192 of finished goods inventory. As of December 30, 2023, noncurrent inventories consisted of $2,051 of raw materials and $1,077 of finished goods inventory. Noncurrent inventories are included in the “Other assets” line item on the Company’s condensed consolidated balance sheets. Noncurrent inventory is anticipated to be consumed beyond our normal operating cycle, but prior to obsolescence.

Investment in Equity Securities

Investment in Equity Securities	6 Months Ended
	Jun. 29, 2024
Equity [Abstract]
Investments in Equity Securities	INVESTMENT IN EQUITY SECURITIES As of June 29, 2024 and December 30, 2023, the carrying amount of equity securities without readily determinable fair values wa s $20,000 and is included in the “Other assets” line item on the Company’s condensed consolidated balance sheets.

Revenue and Contract Liabilitie

Revenue and Contract Liabilities	6 Months Ended
	Jun. 29, 2024
Revenue from Contract with Customer [Abstract]
Revenue and Contract Liabilities	REVENUE AND CONTRACT LIABILITIES Revenue is recognized when, or as, control of a promised product or service transfers to a customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring those products or services. A majority of the Company’s sales are for products sold at a point in time and shipped to customers, for which control is transferred as goods are delivered to the third-party carrier for shipment. The Company receives payment, primarily via credit card, for the sale of products at the time customers place orders and payment is required prior to shipment. Contract liabilities, which are recorded within the “Other current liabilities” line item in the condensed consolidated balance sheets, primarily relate to deferred revenue for product sales for customer payments received in advance of shipment, for outstanding material rights under the initial order program, and for services where control is transferred over time as services are delivered. Other revenue includes fees, which are paid by the customer at the beginning of the service period, for access to online customer service applications and annual account renewal fees for Associates, for which control is transferred over time as services are delivered and are recognized as revenue on a straight-line basis over the term of the respective contracts. NOTE E – REVENUE AND CONTRACT LIABILITIES - CONTINUED The following table presents Other revenue for the periods indicated: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, Other revenue $ 644 $ 755 $ 1,362 $ 1,481 Disaggregation of revenue by geographic region and major product line is included in Segment Information in Note J . The following table provides information about contract liabilities from contracts with customers, including significant changes in the contract liabilities balances during the period: June 29, December 30, Contract liabilities at beginning of period $ 13,910 $ 20,875 Increase due to deferral of revenue at end of period 9,802 13,910 Decrease due to beginning contract liabilities recognized as revenue (11,853) (20,875) Contract liabilities at end of period $ 11,859 $ 13,910

Line of Credit

Line of Credit	6 Months Ended
	Jun. 29, 2024
Line of Credit Facility [Abstract]
Line of Credit	LINE OF CREDIT On August 25, 2020, the Company as borrower, and certain of its material subsidiaries as guarantors, entered into the Second Amended and Restated Credit Agreement (the “Credit Agreement ” ) with Bank of America, N.A. (“Bank of America ” ) as Administrative Agent, Swingline Lender and Letter of Credit Issuer, and the other lenders party thereto. On August 10, 2022, the Company entered into the Second Amendment to the Second Amended and Restated Credit Agreement ("Restated Credit Agreement"), which replaces the Eurodollar Rate, and LIBOR terms and provisions with the Bloomberg Short-Term Bank Yield Index rate (" BSBY"). The Credit Agreement provides for a revolving credit limit for loans to the Company up to $75,000 (the “Credit Facility ” ). In addition, at the option of the Company, and subject to certain conditions, the Company may request to increase the aggregate commitment under the Credit Facility up to an additional $200,000. There was no outstanding debt balance on the Credit Facility as of June 29, 2024 and December 30, 2023. The obligations of the Company under the Credit Agreement are secured by the pledge of the capital stock of certain subsidiaries of the Company, pursuant to a Security and Pledge Agreement. NOTE F – LINE OF CREDIT - CONTINUED Interest on revolving borrowings under the Credit Facility is computed at BSBY , adjusted by features specified in the Credit Agreement. The covenants require the Company’s rolling four-quarter consolidated EBITDA (as defined in the Credit Agreement) to be $100,000 or greater and its ratio of consolidated funded debt to consolidated EBITDA to be equal to or less than 2.0 to 1.0 at the end of each quarter. The Credit Agreement does not include any restrictions on the payment of cash dividends or share repurchases by the Company. Consolidated EBITDA and consolidated funded debt are non-GAAP terms. The Company will be required to pay any balance on this Credit Facility in full at the time of maturity in August 2025. The Company maintains local lines of credit across different markets to secure sufficient working capital. As of June 29, 2024, there was no balance on the local lines of credit. As of December 30, 2023, the balance on the local lines of credit was $786.

Contingencies

Contingencies	6 Months Ended
	Jun. 29, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies	CONTINGENCIES The Company is involved in various lawsuits, claims, and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving its products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company records a liability when a particular contingency is probable and estimable. The Company faces contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While complete assurance cannot be given as to the outcome of these proceedings, management does not currently believe that any of these matters, individually or in the aggregate, will have a material adverse effect on the Company’s financial condition, liquidity or results of operations. It is reasonably possible that a change in the contingencies could result in a change in the amount recorded by the Company in the future.

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jun. 29, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	DERIVATIVE FINANCIAL INSTRUMENTS The Company’s risk management strategy includes the select use of derivative instruments to reduce the effects of volatility in foreign currency exchange exposure on operating results and cash flows. In accordance with the Company’s risk management policies, the Company does not hold or issue derivative instruments for trading or speculative purposes. The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. When the Company becomes a party to a derivative instrument and intends to apply hedge accounting, the Company formally documents the hedge relationship and the risk management objective for undertaking the hedge, the nature of risk being hedged, and the hedged transaction, which includes designating the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. The Company also documents how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company periodically uses derivative instruments to hedge the foreign currency exposure of its net investment in foreign subsidiaries into U.S. dollars. Initially, the Company records derivative assets on a gross basis in its condensed consolidated balance sheets. Subsequently the fair value of derivatives is measured for each reporting period. The effective portion of gains and losses attributable to these net investment hedges is recorded to foreign currency translation adjustment (“FCTA”) within accumulated other comprehensive income (loss) (“AOCI”) to offset the change in the carrying value of the net investment being hedged and will subsequently be reclassified to net earnings in the period in which the investment in the subsidiary is either sold or substantially liquidated. During the six months ended June 29, 2024 and July 1, 2023, the Company entered into and settled European options designated as net investment hedges with notional amounts of $77,345 and $81,343, respectively. For the three and six months ended June 29, 2024 and July 1, 2023, the Company realized gains of $255 and $2,504, respectively, recorded to FCTA within AOCI. The Company assessed the hedge effectiveness under the forward rate method, determining the hedging instruments were highly effective. As of June 29, 2024, there were no derivatives outstanding for which the Company has applied hedge accounting.

Common Stock and Earnings Per S

Common Stock and Earnings Per Share	6 Months Ended
	Jun. 29, 2024
Earnings Per Share [Abstract]
Common Stock and Earnings Per Share	COMMON STOCK AND EARNINGS PER SHARE Basic earnings per share (“EPS”) is based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic EPS based on the time they were outstanding in any period. Diluted EPS is based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted EPS calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised. The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, Net earnings available to common shareholders $ 10,432 $ 17,292 $ 26,969 $ 35,675 Weighted average common shares outstanding - basic 19,073 19,321 19,123 19,302 Dilutive effect of in-the-money equity awards 86 106 107 75 Weighted average common shares outstanding - diluted 19,159 19,427 19,230 19,377 Earnings per common share from net earnings - basic $ 0.55 $ 0.89 $ 1.41 $ 1.85 Earnings per common share from net earnings - diluted $ 0.54 $ 0.89 $ 1.40 $ 1.84 Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be anti-dilutive: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 696 354 541 325 There were no shares repurchased during the three months ended June 29, 2024 and July 1, 2023. During the six months ended June 29, 2024, the Company repurchased and retired 194 shares for $9,483, inclusive of accrued excise tax of $39. There were no shares repurchased during the six months ended July 1, 2023. The excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares outstanding in the above calculations.

Segment Information

Segment Information	6 Months Ended
	Jun. 29, 2024
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company primarily operates as a global direct-selling nutrition, personal health and wellness company that develops and manufactures high quality, science-based nutritional, and personal care products. The Company’s operating segments are identified according to how business activities are managed and evaluated by the chief operating decision maker (“CODM”), our CEO. The CODM manages the business, allocates resources, makes operating decisions, and evaluates performance for a geographic region or market based on net sales. The Company aggregates its direct-selling operating segments (“Direct-selling”) into one reportable segment, as management believes that the Company’s Direct-selling segments exhibit similar long-term financial performance and have similar economic characteristics. The CODM does not evaluate operating segments using asset information, accordingly, the Company does not report asset information by segment. The Company has operating segments, resulting from acquisitions, that are not material to the Company’s net sales. These operating segments are included as a component of “All other” and are included for purposes of reconciliation of net sales to the Company’s Condensed Consolidated Statements of Comprehensive Income. Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, Net sales: Direct-selling $ 211,208 $ 236,795 $ 437,356 $ 483,675 All other 1,661 1,407 3,313 2,887 Consolidated total $ 212,869 $ 238,202 $ 440,669 $ 486,562 No single Associate accounted for 10% or more of net sales for the periods presented. The table below summarizes the approximate percentage of total product revenue for our Direct-selling segment that has been contributed by the Company’s nutritionals, food, and personal care and skincare products for the periods indicated. Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, USANA® Nutritionals 87 % 87 % 87 % 87 % USANA Foods (1) 7 % 7 % 6 % 7 % Personal care and Skincare 5 % 5 % 6 % 5 % All other 1 % 1 % 1 % 1 % (1) Includes the Company’s Active Nutrition line. NOTE J – SEGMENT INFORMATION - CONTINUED Selected Financial Information Financial information, presented by geographic region is listed below: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, Net sales to external customers Asia Pacific Greater China $ 115,513 $ 128,749 $ 243,128 $ 252,569 Southeast Asia Pacific 35,402 39,337 71,467 85,623 North Asia 19,710 25,529 41,131 55,137 Asia Pacific total 170,625 193,615 355,726 393,329 Americas and Europe 42,244 44,587 84,943 93,233 Consolidated total $ 212,869 $ 238,202 $ 440,669 $ 486,562 The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived assets, respectively: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, Net sales: China $ 105,115 $ 117,882 $ 220,869 $ 227,915 United States $ 21,640 $ 23,681 $ 43,804 $ 49,666 South Korea $ 19,298 $ 24,906 $ 40,262 $ 53,792 As of June 29, December 30, Long-lived assets: United States $ 92,465 $ 93,181 China $ 73,531 $ 77,767

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Pay vs Performance Disclosure
Net earnings	$ 10,432	$ 17,292	$ 26,969	$ 35,675

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 29, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization, Consolidation, _2

Organization, Consolidation, and Basis of Presentation (Policies)	6 Months Ended
	Jun. 29, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	USANA Health Sciences, Inc. is a global direct-selling, personal health and wellness company that develops and manufactures high quality, science-based nutritional and personal care products. The Condensed Consolidated Financial Statements (the “Financial Statements”) include the accounts and operations of the Company, which are grouped and presented in two geographic regions: (1) Asia Pacific, and (2) Americas and Europe. Asia Pacific is further divided into three sub-regions: (i) Greater China, (ii) Southeast Asia Pacific, and (iii) North Asia. The countries included in these regions and sub-regions are described below: (1) Asia Pacific - (i) Greater China – Hong Kong, Taiwan, and China. The Company’s business in China is conducted by BabyCare Holdings, Ltd., the Company’s wholly-owned subsidiary. (ii) Southeast Asia Pacific – Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, Indonesia and India (1) . (iii) North Asia – Japan and South Korea. (2) Americas and Europe – United States, Canada, Mexico, Colombia, and Europe (the United Kingdom, France, Germany, Spain, Italy, Romania, Belgium, and the Netherlands). (1) We commenced operations in this market near the end of the fourth quarter of 2023.
Consolidation	The condensed consolidated balance sheet as of December 30, 2023, derived from audited consolidated financial statements, and the unaudited interim condensed consolidated financial information of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X promulgated by the SEC. Accordingly, certain information and disclosures that are normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations.
Use of Estimates	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. In the opinion of the Company’s management, the accompanying interim condensed consolidated financial information contains all adjustments, consisting only of normal recurring adjustments that are necessary to state fairly the Company’s financial position as of June 29, 2024, and results of operations and cash flows for the three and six months ended June 29, 2024 and July 1, 2023.
Reclassification, Comparability Adjustment	Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications relate to the disaggregation of inventory write-downs from changes in inventories within operating activities of the condensed consolidated statements of cash flows.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The standard is intended to provide financial statement users with more disaggregated expense information about a public entity’s reportable segments. ASU 2023-07 requires incremental disclosures related to a public entity’s reportable segments including allowing the disclosure of multiple measures of segment profit or loss, requiring the disclosure of significant segment expenses, and requiring the qualitative disclosure of other segment items. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, and should be adopted retrospectively unless impracticable. Early adoption is permitted. The Company is currently evaluating the impact adoption of the standard will have on its consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The standard is intended to benefit investors by providing more detailed income tax disclosures. ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact adoption of the standard will have on its consolidated financial statements. No other recent accounting pronouncements had, or are expected to have, a material impact on the Company's condensed consolidated financial statements.

Fair Value Measures (Tables)

Fair Value Measures (Tables)	6 Months Ended
	Jun. 29, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Assets and Liabilities	As of June 29, 2024, and December 30, 2023, the following financial assets and liabilities were measured at fair value on a recurring basis using the type of inputs shown: June 29, Fair Value Measurements Using Inputs Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 262,235 $ 262,235 $ — $ — Foreign currency contracts included in other current liabilities (103) — (103) — Deferred compensation liabilities included in other long-term liabilities (4,075) — (4,075) — December 30, Fair Value Measurements Using Inputs Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 258,319 $ 258,319 $ — $ — Foreign currency contracts included in other current liabilities (62) — (62) — Deferred compensation liabilities included in other long-term liabilities (3,137) — (3,137) —

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 29, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: June 29, December 30, Raw materials $ 21,901 $ 19,848 Work in progress 4,306 4,707 Finished goods 35,625 36,899 Inventories $ 61,832 $ 61,454 Noncurrent inventories $ 3,075 $ 3,128

Revenue and Contract Liabilit_2

Revenue and Contract Liabilities (Tables)	6 Months Ended
	Jun. 29, 2024
Revenue from Contract with Customer [Abstract]
Disaggregation of Other Revenue	The following table presents Other revenue for the periods indicated: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, Other revenue $ 644 $ 755 $ 1,362 $ 1,481
Schedule of Contract Liabilities from Contracts with Customers	The following table provides information about contract liabilities from contracts with customers, including significant changes in the contract liabilities balances during the period: June 29, December 30, Contract liabilities at beginning of period $ 13,910 $ 20,875 Increase due to deferral of revenue at end of period 9,802 13,910 Decrease due to beginning contract liabilities recognized as revenue (11,853) (20,875) Contract liabilities at end of period $ 11,859 $ 13,910

Common Stock and Earnings Per_2

Common Stock and Earnings Per Share (Tables)	6 Months Ended
	Jun. 29, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings Per Share	The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, Net earnings available to common shareholders $ 10,432 $ 17,292 $ 26,969 $ 35,675 Weighted average common shares outstanding - basic 19,073 19,321 19,123 19,302 Dilutive effect of in-the-money equity awards 86 106 107 75 Weighted average common shares outstanding - diluted 19,159 19,427 19,230 19,377 Earnings per common share from net earnings - basic $ 0.55 $ 0.89 $ 1.41 $ 1.85 Earnings per common share from net earnings - diluted $ 0.54 $ 0.89 $ 1.40 $ 1.84
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be anti-dilutive: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 696 354 541 325

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 29, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	These operating segments are included as a component of “All other” and are included for purposes of reconciliation of net sales to the Company’s Condensed Consolidated Statements of Comprehensive Income. Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, Net sales: Direct-selling $ 211,208 $ 236,795 $ 437,356 $ 483,675 All other 1,661 1,407 3,313 2,887 Consolidated total $ 212,869 $ 238,202 $ 440,669 $ 486,562
Revenue from External Customers by Products and Services	Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, USANA® Nutritionals 87 % 87 % 87 % 87 % USANA Foods (1) 7 % 7 % 6 % 7 % Personal care and Skincare 5 % 5 % 6 % 5 % All other 1 % 1 % 1 % 1 % (1) Includes the Company’s Active Nutrition line.
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area	Financial information, presented by geographic region is listed below: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, Net sales to external customers Asia Pacific Greater China $ 115,513 $ 128,749 $ 243,128 $ 252,569 Southeast Asia Pacific 35,402 39,337 71,467 85,623 North Asia 19,710 25,529 41,131 55,137 Asia Pacific total 170,625 193,615 355,726 393,329 Americas and Europe 42,244 44,587 84,943 93,233 Consolidated total $ 212,869 $ 238,202 $ 440,669 $ 486,562
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived assets, respectively: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, Net sales: China $ 105,115 $ 117,882 $ 220,869 $ 227,915 United States $ 21,640 $ 23,681 $ 43,804 $ 49,666 South Korea $ 19,298 $ 24,906 $ 40,262 $ 53,792 As of June 29, December 30, Long-lived assets: United States $ 92,465 $ 93,181 China $ 73,531 $ 77,767

Organization, Consolidation, _3

Organization, Consolidation, and Basis of Presentation (Details)	6 Months Ended
	Jun. 29, 2024 region
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of geographic regions	2
Number of sub geographical regions	3

Fair Value Measures - Schedule

Fair Value Measures - Schedule Of Assets And Liabilities Measured At Fair Value (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Fair Value Disclosures [Line Items]
Foreign currency contracts included in other current liabilities	$ (103)	$ (62)
Deferred compensation liabilities included in other long-term liabilities	(4,075)	(3,137)
Level 1
Fair Value Disclosures [Line Items]
Foreign currency contracts included in other current liabilities	0	0
Deferred compensation liabilities included in other long-term liabilities	0	0
Level 2
Fair Value Disclosures [Line Items]
Foreign currency contracts included in other current liabilities	(103)	(62)
Deferred compensation liabilities included in other long-term liabilities	(4,075)	(3,137)
Level 3
Fair Value Disclosures [Line Items]
Foreign currency contracts included in other current liabilities	0	0
Deferred compensation liabilities included in other long-term liabilities	0	0
Money Market Funds
Fair Value Disclosures [Line Items]
Money market funds included in cash equivalents	262,235	258,319
Money Market Funds | Level 1
Fair Value Disclosures [Line Items]
Money market funds included in cash equivalents	262,235	258,319
Money Market Funds | Level 2
Fair Value Disclosures [Line Items]
Money market funds included in cash equivalents	0	0
Money Market Funds | Level 3
Fair Value Disclosures [Line Items]
Money market funds included in cash equivalents	$ 0	$ 0

Fair Value Measures - Narrative

Fair Value Measures - Narrative (Details) - USD ($)	Jun. 29, 2024	Dec. 30, 2023
Fair Value, Recurring
Fair Value Disclosures [Line Items]
Nonfinancial assets, fair value disclosure	$ 0	$ 0

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 21,901	$ 19,848
Work in progress	4,306	4,707
Finished goods	35,625	36,899
Inventories	61,832	61,454
Noncurrent inventories	$ 3,075	$ 3,128

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Inventory [Line Items]
Noncurrent inventories	$ 3,075	$ 3,128
Raw Materials
Inventory [Line Items]
Noncurrent inventories	1,883	2,051
Finished Goods
Inventory [Line Items]
Noncurrent inventories	$ 1,192	$ 1,077

Investment in Equity Securiti_2

Investment in Equity Securities - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023
Equity [Line Items]
Impairment of securities	$ 0	$ 0	$ 0	$ 0
Other Assets
Equity [Line Items]
Equity securities without readily determinable fair value	$ 20,000,000		$ 20,000,000		$ 20,000,000

Revenue and Contract Liabilit_3

Revenue and Contract Liabilities - Schedule of Other Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Revenue from Contract with Customer [Abstract]
Other revenue	$ 644	$ 755	$ 1,362	$ 1,481

Revenue and Contract Liabilit_4

Revenue and Contract Liabilities - Schedule Of Contract Liabilities From Contract With Customers (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 29, 2024	Dec. 30, 2023
Movement in Contract Liabilities [Roll Forward]
Contract liabilities at beginning of period	$ 13,910	$ 20,875
Increase due to deferral of revenue at end of period	9,802	13,910
Decrease due to beginning contract liabilities recognized as revenue	(11,853)	(20,875)
Contract liabilities at end of period	$ 11,859	$ 13,910

Line of Credit (Details)

Line of Credit (Details)	6 Months Ended
	Jun. 29, 2024 USD ($)	Dec. 30, 2023 USD ($)
Line of Credit Facility [Line Items]
Line of credit - short term	$ 0	$ 786,000
Line of Credit
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	75,000,000
Line of credit facility, additional increase in maximum borrowing capacity	200,000,000
Outstanding debt	0	$ 0
Line of Credit | Amended and Restated Credit Agreement
Line of Credit Facility [Line Items]
Debt instrument covenant, EBITDA	$ 100,000,000
Ratio of consolidated funded debt to EBITDA (less than)	2

Derivative Financial Instrume_2

Derivative Financial Instruments - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Derivative [Line Items]
Gain on derivative	$ 255	$ 2,504	$ 255	$ 2,504
Foreign Exchange Option | Designated as Hedging Instrument
Derivative [Line Items]
Derivative notional amount	$ 77,345		$ 77,345
Foreign Exchange Forward | Designated as Hedging Instrument
Derivative [Line Items]
Derivative notional amount		$ 81,343		$ 81,343

Common Stock and Earnings Per_3

Common Stock and Earnings Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Earnings Per Share [Abstract]
Net earnings available to common shareholders	$ 10,432	$ 17,292	$ 26,969	$ 35,675
Weighted average common shares outstanding - basic (in shares)	19,073	19,321	19,123	19,302
Dilutive effect of in-the-money equity awards (in shares)	86	106	107	75
Weighted average common shares outstanding - diluted (in shares)	19,159	19,427	19,230	19,377
Earnings per common share from net earnings - basic (in dollars per share)	$ 0.55	$ 0.89	$ 1.41	$ 1.85
Earnings per common share from net earnings - diluted (in dollars per share)	$ 0.54	$ 0.89	$ 1.40	$ 1.84

Common Stock and Earnings Per_4

Common Stock and Earnings Per Share - Schedule of Shares not Included in the Computation of Diluted EPS (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share (in shares)	696	354	541	325

Common Stock and Earnings Per_5

Common Stock and Earnings Per Share - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Earnings Per Share [Abstract]
Common stock repurchased and retired (in shares)			194,000	0
Common stock repurchased and retired			$ 9,483
Accrued excise tax for repurchase of common stock			39	$ 0
Stock repurchased during period, shares (in shares)	0	0
Stock repurchased, excise tax payable	$ 39		39
Remaining authorized repurchase amount	$ 61,703		$ 61,703

Segment Information - Narrative

Segment Information - Narrative (Details)	6 Months Ended
	Jun. 29, 2024 segment
Segment Reporting [Abstract]
Number of reportable segments	1

Segment Information - Schedule

Segment Information - Schedule of Segment Reporting Information, by Operating Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Segment Information [Line Items]
Net sales	$ 212,869	$ 238,202	$ 440,669	$ 486,562
Operating Segments | Direct Selling
Segment Information [Line Items]
Net sales	211,208	236,795	437,356	483,675
Operating Segments | All other
Segment Information [Line Items]
Net sales	$ 1,661	$ 1,407	$ 3,313	$ 2,887

Segment Information - Schedul_2

Segment Information - Schedule of Revenue Percentage By Product (Details) - Product Concentration Risk - Revenue Benchmark	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
USANA® Nutritionals
Segment Information [Line Items]
Concentration risk, percentage	87%	87%	87%	87%
USANA Foods
Segment Information [Line Items]
Concentration risk, percentage	7%	7%	6%	7%
Personal care and Skincare
Segment Information [Line Items]
Concentration risk, percentage	5%	5%	6%	5%
All other
Segment Information [Line Items]
Concentration risk, percentage	1%	1%	1%	1%

Segment Information - Consolida

Segment Information - Consolidated Net Sales and Long Lived Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 212,869	$ 238,202	$ 440,669	$ 486,562
Asia Pacific total
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	170,625	193,615	355,726	393,329
Greater China
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	115,513	128,749	243,128	252,569
Southeast Asia Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	35,402	39,337	71,467	85,623
North Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	19,710	25,529	41,131	55,137
Americas and Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	42,244	44,587	84,943	93,233
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	105,115	117,882	220,869	227,915
Long-lived assets:	73,531		73,531		$ 77,767
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	21,640	23,681	43,804	49,666
Long-lived assets:	92,465		92,465		$ 93,181
South Korea
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 19,298	$ 24,906	$ 40,262	$ 53,792